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Background: Prescriptions of off-label dosing non-vitamin K antagonist oral anticoagulant (NOACs) areis common in the daily practice, especially for Asian patients with atrial fibrillation (AF). In the present study, we investigated the impacts of inappropriate dosing of NOACs on clinical outcomes. 
Methods: We used medical data from a multi-center healthcare system in Taiwan which included 2,068, 5,135, 2,589, 1,483, and 2,342 patients taking dabigatran, rivaroxaban, apixaban, edoxaban and warfarin, respectively. The risks of ischemic stroke/systemic embolism (IS/SE) and major bleeding of AF patients treated with under-dosing or over-dosing NOACs were compared to on-label dosing NOACs and warfarin.
Results: Around 69%, 27% and 5% of AF patients were treated with on-label dosing, off-label under-dosing, and off-label over-dosing NOACs, respectively. Compared to on-label dosing, under-dosing NOACs were associated with a significantly higher risk of IS/SE (aHR 1.59, 95% CI 1.25-2.02; P < .001) and a similar risk of major bleeding (aHR 0.80, 95% CI 0.50-1.27; P = 0.337), while over-dosing NOACS NOACs were associated with a significantly higher risk of major bleeding (aHR 2.01, 95% CI 1.13-3.56; P = 0.017) and a similar risk of IS/SE (aHR 1.24, 95% CI 0.74-2.07; P = 0.415). Compared to warfarin, the four on-label dosing NOACs were all associated with a comparable risk of IS/SE and a significantly lower risk of major bleeding, while off-label under-dosing NOACs were associated with a higher risk of IS/SE (aHR 1.46, 95%CI 1.09-1.96; P = 0.012) and off-label over-dosing NOACs were not associated with a lower risk of major bleeding (aHR 1.07, 95%CI 0.60-1.90; P = 0.814).
Conclusions: Around 3 in 10 Asian AF patients were treated with off-label dosing NOACs in the daily practice. Compared to on-labeling NOAC dosing, underdosing was associated with a higher risk of IS/SE without a lower risk of major bleeding while overdosing was associated with a higher risk of major bleeding without a lower risk of IS/SE. Even for Asian AF patients at a higher risk of bleeding, NOACs should still be prescribed at the dosing following the clinical trial settings criteria and guideline recommendations.




Stroke prevention is central to the managements of patients with atrial fibrillation (AF), and long-term use of oral anticoagulants (OACs) could effectively reduces the risk of stroke.(1) NonThe non-vitamin K antagonist oral anticoagulants (NOACs) provide an alternative options option to the Vitamin K antagonists (VKA, eg.warfarin) and are becoming the preferred choice for stroke prevention in guidelines. ADDIN EN.CITE (2,3) 
Since routine monitoring of drug concentration is not necessary for NOACs, the selection of appropriate dose of NOACs according to the dosage criteria defined in randomized controlled trials (RCTs) is very important. Nevertheless, prescriptions of off-label dosing of NOACs remained as a major problem in the daily practice. In the a prior previous report from the United States, around 9.4% of AF patients received off-label under-dosed NOACs, which and were was associated with a worse clinical outcome. ADDIN EN.CITE (4) Since the Asian population had is associated with a higher bleeding risk such as intracranial hemorrhage (ICH), ADDIN EN.CITE (5,6) physicians generally tend ed to prescribed low-dosed NOACs for Asian AF patients in the daily clinical practice. In Taiwan, standard-dosed dabigatran (150mg twice daily), rivaroxaban (20mg per day) and apixaban (5mg twice daily) were prescribed in only 12%, 6% and 38% of AF patients, respectively. ADDIN EN.CITE (7) Despite the high prescription rates of low-dosed NOACs, NOACs were still associated with a comparable or even lower risk of ischemic stroke/systemic embolism (IS/SE) compared to warfarin in most some real-world data from in Asian cohorts. ADDIN EN.CITE (8-10) These findings raise a question about whether there should be a lower dose of NOACs, a so- called “Asian dose”, for Asian AF patients. Since information about renal function and body weight was usually not available in prior real-world studies, how manythe actual percentages of these low-dose NOACs that were actually “off-label low-dose” and its their impacts on clinical outcomes were remains unknown. 




The study is based in part on data from the Chang Gung Research Database provided by Chang Gung Memorial Hospital. The interpretation and conclusions contained herein do not represent the position of Chang Gung Memorial Hospital (CGMH). We conducted the retrospective observational study by using the patients’ data came from the CGMH Medical System. The CGMH Medical system composed of 3 major teaching hospitals and 4 tertiary care medical centers with a total of 10,050 beds and admits around 280,000 patients per year, which and is the largest healthcare provider in Taiwan until now. ADDIN EN.CITE (11) In 2015, the emergent and outpatient department visits to CGMH Medical system were 500,000 and 8,500,000, respectively, approximately 1/10 of the Taiwanese medical service annually. ADDIN EN.CITE (11) The advantage of CGMH medical database is that each patient’s detailed chart record, diagnosis, laboratory, and imaging data are available. ADDIN EN.CITE (12) The personal information and identification number of each patient are encrypted and de-identified by using a consistent encrypting procedure; therefore, informed consent was waived for this study. Our study was approved by the Institutional Review Board of the Chang Gung Medical Foundation (201802075B0).
Study cohort
The flowchart of study design and patient enrollment is shown in Figure 1. The CGMH medical database was retrospectively searched for patients  20 years in whom new-onset AF was diagnosed from July 1st, 2010 to September 30st, 2018 (n = 53,852). There were 15,841 patients treated with OACs after June 1st, 2012. Patients with a diagnosis of pulmonary embolism or deep venous thrombosis (n = 73), post valvular surgery (n = 215), mitral stenosis (n = 19), or end stage renal disease (n = 94) were excluded from the present study. Besides, patients whose information about body weight and serum creatinine were not available within 6 months before the dates when OACs were prescribed were also excluded (n = 1,823). Finally, a total of 2,068, 5,135, 2,589, 1,483, and 2,342 AF patients treated with dabigatran, rivaroxaban, apixaban, edoxaban and warfarin, respectively, have constituted the study population. 
Eligibility and dosage adjustment of NOACs
In the present study, patients treated with NOACs were defined as “off-label underdosing”, “on-label dosing”, and “off-label overdosing” generally based on the dosage reduction criteria of pivotal NOACs randomized trials and recommendations of international society guidelines. ADDIN EN.CITE (13-21) Of note, there were no prospective dose-reduction criteria for patients treated with dabigatran in the RE-LY study. ADDIN EN.CITE (13) However, dabigatran 110 mg bid was suggested for patients aged > 80 years, age 75-80 years with a high risk of bleeding or use of concomitant verapamil based on the prior study and experts’ opinions. ADDIN EN.CITE (19,22,23) Without any of the above indications, dabigatran 150 mg bid was recommended. For rivaroxaban, Taiwan Food and Drug Administration (FDA) approved either standard-dose regimen (20/15 mg/day), following the ROCKET AF dosage criteria, or low-dose regimen (15/10 mg/day), following the J-ROCKET AF dosage criteria, for stroke prevention in AF patients. ADDIN EN.CITE (14,15,24) Therefore, patients following either ROCKET-AF or J-ROCKET AF dosage criteria for rivaroxaban were defined as on-label dosing in the present study. In case of apixaban, if 2 of 3 criteria (age > 80 years, body weight < 60 kg, and measured serum creatinine > 1.5 mg/dl) were met, the dosage of apixaban was reduced from 5 mg bid to 2.5 mg bid. ADDIN EN.CITE (16) For patients with a creatinine clearance rate (CCr) between 15-30 ml/min, apixaban 2.5 mg bid was recommended. ADDIN EN.CITE (19) For edoxaban, if any of 3 criteria (body weight < 60 kg, CCr < 50 ml/min, and concomitant use of P-glycoprotein inhibitor) was met, the daily dose of edoxaban was reduced from 60mg to 30 mg. ADDIN EN.CITE (17) Of note, prescriptions of dabigatran for patients with a CCr < 30 ml/min or use of rivaroxaban, apixaban amd edoxaban for patients with a CCr < 15 ml/min were defined as overdosing in our study. ADDIN EN.CITE (19)
Study outcomes
We reported the clinical outcomes of IS/SE and major bleeding for AF patients treated with NOACs. All study outcomes were defined on the basis of the first discharge diagnosis to avoid misclassification. The major bleeding events were defined as the total number of hospitalized events of ICH, gastrointestinal bleeding, and other sites of critical bleeding. The follow-up period was defined as the duration from the drug index date until the occurrence of study outcomes, mortality, or until the end date of the study period (September 30th, 2018), whichever came first. The risks of clinical events of underdosing and overdosing groups were compared to that of on-label dosing group. Besides, the risks of clinical events of NOACs in each dosing groups were compared to  that of warfarin.
Statistical analysis




Clinical characteristics of all AF patients and those in each dosing groups
The clinical characteristics of study population are shown in Table 1.  There were 7,764 (68.9%), 2,999 (26.6%), and 512 (4.5%) patients treated with on-label dosing, off-label under dosing, and off-label over-dosing NOACs, respectively. Compared to on-label dosing group, patients receiving under-dosing NOACs were younger with a lower mean CHA2DS2-VASc and HAS-BLED scores, while patients receiving over-dosing NOACs were older and had a higher CHA2DS2-VASc and HAS-BLED scores. The CCr was higher in under-dosing and lower in over-dosing groups compared to on-label dosing one. Baseline medications were not significantly different among three groups, except for a higher prescription rate of verapamil in the over-dosing group.   
The proportions of different dosing groups of 4 NOACs are shown in Figure 2. The highest rate of on-label dosing was observed for rivaroxaban (81%), followed by edoxaban (67%), apixaban (65%) and dabigatran (44%). For all NOACs, the percentages of underdosing (17%-48%) were higher than overdosing (2-10%). The bBaseline characteristics of each NOACs are summarized in Supplemental Figure I to IV.
Clinical outcomes of patients treated with off-label dosing vs. on-label dosing NOACs
Overall, those 2,999 patients taking under-dosing NOACs were associated with a significantly higher risk of IS/SE (adjusted hazard ratio [aHR] 1.59, 95% confidential interval [CI] 1.25-2.02; P < .001) and a similar risk of major bleeding (aHR 0.80, 95% CI 0.50-1.27; P = 0.337) compared to 7,764 patients taking on-label dosing NOACs, after the adjustment for age, gender, CHA2DS2-VASc score, HAS-BLED score and CCr (Figure 3A). Of note, patients taking off-label under-dosing rivaroxaban (n = 858) and apixaban (n = 799) were associated with a significantly higher risk of IS/SE than those treated with on-label dosing rivaroxaban (n = 4,191) and apixaban (n = 1,677). 
In contrast, those 512 patients taking off-label over-dosing NOACS were associated with a significantly higher risk of major bleeding (aHR 2.01, 95% CI 1.13-3.56; P = 0.017) and a similar risk of IS/SE (aHR 1.24, 95% CI 0.74-2.07; P = 0.415) than patients taking on-label dosing NOACs (Figure 3B). The oOver-dosing rivaroxaban (n = 86) was associated with a significantly higher risk of IS/SE (aHR 2.53, 95% CI 1.17-5.45; P = 0.018) and major bleeding (aHR 3.06, 95% CI 1.10-8.49; P = 0.032) compared to on-label dosing (n = 4,191). 
Subgroup analysis
Figure 4 shows the comparisons of off-label underdosing and on-label dosing in different subgroups of patients. Consistent with the results of principal analysis, patients treated with off-label under-dosing NOACs were associated with a higher risk of ISS/E but a comparable risk of major bleeding than those treated with on-label dosing across all subgroups (all Pint >0.05). Figure 5 shows the comparisons of off-label overdosing and on-label dosing in different subgroups of patients. The increased risk of major bleeding for off-label over-dosing compared to on-label dosing was observed in different subgroups (all Pint >0.05).
Clinical outcomes of NOACs in dDifferent NOAC dosing groups compared to warfarin





In the present study, we investigated the clinical impacts of inappropriate dosing of four NOACs among Asian AF population in the daily practice. Our principal findings are as follows: (i) there were around 27% and 5% of patients were treated with off-label under-dosing and overdoing NOACs, respectively; (ii) compared to on- label dosing NOACs, off-label under-dosing NOACs were associated with a significantly higher risk of IS/SE especially for rivaroxaban and apixaban, whereas off-label overdosing NOACs were associated with a significantly higher risk of major bleeding especially for dabigatran and rivaroxaban; and (iii) compared to warfarin, all four on-labeling dosing NOACs were associated with a comparable risk of IS/SE and a lower risk of major bleeding, whereas underdoing was associated with a higher risk of IS/SE and overdosing was not associated with a risk of major bleeding. These results highlighted the importance of prescriptions of NOACs at the on-labeling dosing even for Asians AF patients who were more prone to bleeding. 
Prevalence of off-label dosing NOACs for stroke prevention in AF patients 
Although there arwere lots ofvarious registry and administrative studies investigating the effectiveness and safety of NOACs for AF stroke prevention in real-world practice, a key and fundamental limitation is the inability to calculate CCr due to the absence of data about body weight and serum creatinine in most of themdatasets, making it difficult to distinguish whether patients were actually treated with an appropriate dosing NOAC or not. Until now, there have been were only a few clinical studies evaluating the impacts of inappropriate dosing of NOACs in AF patients. 
In the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) study, around 13% of patients received NOACs at an inappropriate dosing (underdoing in 9.4% and overdosing in 3.4%) which were associated with an increased risk of clinical events. ADDIN EN.CITE (4) Yao et al studied 14,865 AF patients treated with apixaban, dabigatran, or rivaroxaban. ADDIN EN.CITE (25) Among the 1,473 patients with a renal indication for dose reduction, 43% were overdosed, which was associated with a higher risk of major bleeding but no significant difference in risk of stroke. Among the 13,392 patients with no renal indication for dose reduction, 13% were potentially underdosed. This underdosing was associated with a higher risk of stroke but no significant difference in risk of major bleeding in apixaban-treated patients. Compared to these 2 studies of the United States, the percentage (32%) of off-labeling dosing, mainly due to underdosing (27%), was higher in our study including Chinese AF patients. This reflects how physicians tended to prescribe low-dosed NOACs, even against the standard labeling, for Asian AF patients probably due to the concern of the higher risk of bleeding for Asians and the lacking of data regarding this issue. 
Impacts oOff-label dosing NOACs on clinical outcomes in Asian AF patients  
Similar to previous studies of non-Asians, ADDIN EN.CITE (4,25) we showed that underdosing NOACs were associated with an 59% and 46% increased risk of IS/SE compared to on-label dosing NOACs and warfarin, respectively. Of note, the underdoing may was not be able to link to a associated with a significantly lower risk of major bleeding compared to on-label dosing NOACs (aHR 0.80, 95% CI 0.50-1.27), the reason why they were chosenwere often prescribed. The increased risk of IS/SE for underdoing NOACs was particularly evident for rivaroxaban and apixaban. Our data was are consistent with the previous study by Yao et al. showing that under-dosed apixaban in patients without severe renal impairment was associated with a nearly 5-fold increased risk of stroke but without a reduction of major bleeding when compared with those taking on-label dosing apixaban. ADDIN EN.CITE (25) For rivaroxaban, the off-label underdosing (10mg/day for patients with a CCr > 50 min/day) defined in our study was associated with a 2-fold increased risk of IS/SE compared to on-label dosing (aHR 2.00, 95% CI 1.37-2.92) and warfarin (aHR 1.92, 95% CI 1.28-2.87), and therefore, should be avoided. 
Interestingly, we did not observe a higher risk of IS/SE for patients treated with underdoing dabigatran or edoxaban. Dabigatran 110 mg twice daily was the only low-dosed NOAC without any specified dosage criteria which was compared to warfarin in the randomized trial. ADDIN EN.CITE (13) The Danish registry showed that both dabigatran 150 mg and 110 mg were associated with a comparable risk of thromboembolism and a lower risk of major bleeding when compared with warfarin in AF patients. ADDIN EN.CITE (26,27)  Indeed, Lee et al. analyzed 1,834 non-valvular AF patients treated with warfarin, dabigatran 150 mg, and dabigatran 110 mg, ADDIN EN.CITE (28) and the dabigatran 110 mg group was further classified as off-label or on-label dosing following European labeling. ADDIN EN.CITE (22) The results indicated that both on-label and off-label dabigatran 110 mg displayed a comparable efficacy and a lower risk of major bleeding compared to warfarin. ADDIN EN.CITE (28) Our results were consistent with above studies showing that even the guideline-discordant use of dabigatran 110 mg demonstrated a similar efficacy compared to on-label dosing dabigatran or warfarin. However, further prospective studies are necessary to evaluate the optimal dosage of dabigatran in Asian AF patients. 
In case of edoxaban, our results indicated that off-label under-dosing of edoxaban was not associated with a significantly higher risk of IS/SE compared to on-label dosing edoxaban (aHR 1.43, 95% CI 0.53-3.89) or warfarin (aHR 1.53, 95% CI 0.64-3.65). However, our results should not be interpreted as off-labeling underdosing edoxaban could be prescribed for Asian AF patients since the non-significant increase in risk of IS/SE may be because of the relatively small sample size of edoxaban users in our study. Furthermore, even with on-label dosing edoxaban, the risk of major bleeding was not higher than off-labeling underdosing edoxaban and still significantly lower than warfarin (aHR 0.39, 95% CI 0.15-0.99). In the ENGAGE AF-TIMI-48 trial, although low-dosed edoxaban regimen (30/15 mg) had a similar risk of stroke/systemic embolic event (HR 1.13, 95% CI 0.97-1.31) compared to warfarin, the risk of ischemic stroke withof low-dosed edoxaban regimen was higher (HR 1.41m, 95% CI 1.19-1.67). ADDIN EN.CITE (17) Therefore, off-label low-dosing edoxaban should generally not be considered for the Asian AF population. 
Limitations
There are several limitations of the present study. Firstly, the present study is a retrospective study, and therefore, the results from the individual NOAC may be confounded by the bias of prescriptions (e.g., a perceived risk may result in conscious avoidance in use of specific NOAC in specific patient populations). Second, although the baseline differences between different groups have been adjusted using multivariable regression analysis, some residual unmeasured confounders could still be present. Third, our study was performed in an intention to treat design, and did not take the changes of dosages of NOACs which may result in different categorizations of patients into considerations. Lastly, the present study only investigated Chinese patients and whether our results can be extrapolated to other Asian races remains unclear.   
Conclusion 
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Figure 1 A flowchart of patient enrollment. Among 53,852 newly-diagnosed AF patients, 15,841 of them were treated with oral anticoagulants (OACs) after June 1st, 2012. A total of 2,068, 5,135, 2,589, 1,483, and 2,342 AF patients treated with dabigatran, rivaroxaban, apixaban, edoxaban and warfarin, respectively, have constituted the study population. 
AF = atrial fibrillation; NOACs = non-vitamin K antagonist oral anticoagulants; OACs = oral anticoagulants 

Figure 2 Proportions of different dosing groups of 4 NOACs. Overall, around 69%, 27% and 5% of patients were treated with on-label dosing, off-label under dosing, and off-label over-dosing NOACs, respectively. The highest rate of on-label dosing was observed for rivaroxaban (81%), followed by edoxaban (67%), apixaban (65%) and dabigatran (44%). For all NOACs, the percentages of underdosing (17%-48%) were higher than overdosing (2-10%). 
NOACs = non-vitamin K antagonist oral anticoagulants

Figure 3 Clinical outcomes of patients treated with off-label dosing vs. on-label dosing NOACs. Compared to on-label dosing, under-dosing NOACs were associated with a significantly higher risk of IS/SE (aHR 1.59, 95% CI 1.25-2.02; P < .001) and a similar risk of major bleeding (aHR 0.80, 95% CI 0.50-1.27; P = 0.337)(Figure 3A), while over-dosing NOACS were associated with a significantly higher risk of major bleeding (aHR 2.01, 95% CI 1.13-3.56; P = 0.017) and a similar risk of IS/SE (aHR 1.24, 95% CI 0.74-2.07; P = 0.415)(Figure 3B).
*Adjustment for age, gender, CHA2DS2-VASc score, HAS-BLED score and CCr
aHR = adjusted hazard ratio; CCr = creatinine clearance rate; CI = confidence interval; IS/SE = ischemic stroke/systemic embolism; NOACs = non-vitamin K antagonist oral anticoagulant

Figure 4 Comparisons of off-label underdosing and on-label dosing NOACs in different subgroups of patients. Consistent with the results of principal analysis, patients treated with off-label under-dosing NOACs were associated with a higher risk of ISS/E but a comparable risk of major bleeding than those treated with on-label dosing across all subgroups (all Pint >0.05).
*Adjustment for age, gender, CHA2DS2-VASc score, HAS-BLED score and CCr
aHR = adjusted hazard ratio; CCr = creatinine clearance rate; CI = confidence interval; IS/SE = ischemic stroke/systemic embolism; NOACs = non-vitamin K antagonist oral anticoagulant

Figure 5 Comparisons of off-label overdosing and on-label dosing NOACs in different subgroups of patients. The increased risk of major bleeding for off-label over-dosing compared to on-label dosing was consistently observed in different subgroups (all Pint >0.05).
*Adjustment for age, gender, CHA2DS2-VASc score, HAS-BLED score and CCr
aHR = adjusted hazard ratio; CCr = creatinine clearance rate; CI = confidence interval; IS/SE = ischemic stroke/systemic embolism; NOACs = non-vitamin K antagonist oral anticoagulant

Figure 6 Clinical outcomes of NOACs in different dosing groups compared to warfarin. Patients taking four on-label dosing NOACs were all associated with a comparable risk of IS/SE and a significantly lower risk of major bleeding compared to those receiving warfarin (Figure 6A). In contrast, patients treated with off-label under-dosing NOACs, especially for rivaroxaban (aHR 1.92, 95%CI 1.28-2.87; P = 0.002) and apixaban (aHR 1.71, 95%CI: 1.10-2.66; P = 0.017), were associated with a significantly higher risk of IS/SE than those treated with warfarin (Figure 6B). Patients treated with off-label over-dosing NOACs were associated with a comparable risk of IS/SE (aHR 1.13, 95%CI 0.66-1.93; P = 0.663) and major bleeding (aHR 1.07, 95%CI 0.60-1.90; P = 0.814) compared to those treated with warfarin (Figure 6C).
*Adjustment for age, gender, CHA2DS2-VASc score, HAS-BLED score and CCr
aHR = adjusted hazard ratio; CCr = creatinine clearance rate; CI = confidence interval; IS/SE = ischemic stroke/systemic embolism; NOACs = non-vitamin K antagonist oral anticoagulant
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